ReviewInternational journal of nanomedicine2026
The Current Application Prospects of Nanomedicine in Renal Ischemia-Reperfusion Injury.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal ischemia-reperfusion injury (RIRI) is one of the main causes of acute kidney injury (AKI), and its pathological mechanism is complex, mainly involving multiple pathological processes such as oxidative stress outbreak, uncontrolled inflammatory response, abnormal cell apoptosis, and microcirculatory disorders. Currently, there is a lack of efficient and accurate diagnosis and treatment strategies in clinical practice. As a cross discipline integrating nanomaterials, medicine and biology, nanomedicine has shown unique advantages and broad application prospects in the diagnosis and treatment field of RIRI in recent years. Its core carriers include inorganic nanoparticles, polymeric nanoparticles, nanoenzymes, extracellular vesicles, cell membrane camouflage nanoparticles and injectable nanohydrogels. The diagnosis and treatment system based on nanomedicine can breakthrough the limitations of traditional diagnosis and treatment models, and play an important role in early accurate diagnosis, targeted drug delivery, precise treatment of lesion sites, and prolonged drug circulation time in RIRI. It effectively solves pain points such as strong toxicity, short circulation time, and poor targeting of single drugs. However, the specific mechanism of action of nanomedicine in RIRI has not been fully elucidated, and issues such as the biosafety, in vivo metabolic patterns, and clinical translation bottlenecks of nanomedicine still need to be urgently addressed. This review aims to systematically review the application and mechanism research progress of nanomedicine in RIRI, briefly explain the core pathological mechanism of RIRI, focus on the application effects and mechanisms of nanomedicine systems composed of different types of nanocarriers in RIRI diagnosis and treatment, summarize the current research challenges and look forward to future development directions, providing theoretical basis and practical reference for in-depth research, technological breakthroughs, and clinical translation of nanomedicine in the field of RIRI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.